{
    "ucits": true,
    "type": "ETF",
    "derivatives": true,
    "swaps": true,
    "leverage": false,
    "inverse": false,
    "replication_method": "synthetic",
    "complex_factors": "Use of swaps and derivatives for replication, exposure to structured products like CLOs, embedded derivatives",
    "classification": "complex",
    "supporting_data": "The VanEck Genomics and Healthcare Innovators UCITS ETF uses derivatives including swaps, futures, options, currency forwards, and non-deliverable forwards as part of its replication strategy. It employs synthetic replication methods involving total return swaps to replicate the index performance, which introduces counterparty and collateral risks that are difficult for retail investors to understand. The ETF invests in structured products and derivatives, which under MiFID II Article 57 and ESMA guidelines are considered complex due to embedded derivatives and the opacity of payoff structures. Although UCITS ETFs are generally presumed non-complex, this presumption is overturned when the ETF uses derivatives integral to its investment objective, as here. The ETF does not use significant leverage beyond UCITS limits, but the synthetic replication and derivative use classify it as complex. According to MiFID II and ESMA supervisory guidance, such ETFs require an appropriateness assessment for retail investors to ensure understanding of risks. Therefore, despite being UCITS, the ETF is complex under MiFID II due to its synthetic replication and derivative exposure."
}